Physician-led education on blood filtration, the differences between techniques, and the importance of evidence-based medical indications.
INUSpheresis is not currently offered at AlyneMD. This page provides educational information; a consultation does not reserve an INUSpheresis treatment.

A Scientific, Targeted Approach to Blood Filtration
Apheresis is a group of procedures that separate or remove selected blood components. Different methods have different indications, evidence and risks. INUSpheresis is discussed here for education and is not currently offered at AlyneMD. During a consultation, we can review your concerns and discuss available care or an appropriate specialist referral.
INUSpheresis uses double-filtration plasmapheresis to separate and filter plasma before returning it to the patient. It is not interchangeable with every form of apheresis. Published evidence for broad wellness or longevity benefits remains limited, and potential benefits must be considered alongside procedure-specific risks.
.webp)

Changes in circulating substances do not, by themselves, establish a lasting health benefit. Treatment decisions require an indication-specific assessment.
.webp)
These procedures differ in their mechanisms, indications, evidence and risks. Comparing them does not mean they are interchangeable or available at the same clinic. INUSpheresis is not currently offered at AlyneMD; this page is educational.
| EBOO | INUSpheresis | Plasma Exchange (TPE) | |
|---|---|---|---|
| What it is | Extracorporeal blood oxygenation and ozonation | Double filtration plasmapheresis, also called cascade filtration | Full plasma removal and replacement |
| Core action | Adds. Blood passes a gas exchange filter where it meets a medical oxygen and ozone mixture, then returns to you | Filters. Plasma is separated from your cells, passed through a second size selective filter, and your own plasma is returned | Replaces. Your plasma is removed and substituted with albumin, donor plasma, or a combination |
| What it addresses | Oxidative signaling and microcirculation. The circuit filter also captures some lipid and particulate debris | Larger circulating molecules including inflammatory cytokines, immune complexes, autoantibodies, oxidized lipids, and fibrinogen | Plasma broadly, including pathogenic antibodies, along with beneficial components such as clotting factors and immunoglobulins |
| Selectivity | Not a removal therapy. Primary effect is oxidative signaling | Selective. Sieves by molecular size and retains albumin and smaller beneficial proteins | Non selective. Removes plasma without distinguishing helpful from harmful |
| Replacement fluid | None | Usually none. Your own filtered plasma is returned | Required. Albumin and or donor plasma |
| Typical session | About 45 to 60 minutes | About 2 to 3 hours | About 2 to 4 hours |
| Access | Two IV sites, typically one per arm | Two IV sites | Two large bore IV sites, or central access in some cases |
| Typical course | Usually a series, spaced per physician plan | Often an initial session or two, then reassessment with labs | A defined series determined by indication |
| Often chosen for | Oxidative stress, inflammation, circulation, energy and recovery goals | A measurable inflammatory or environmental burden identified on testing | Established autoimmune and neurologic indications |
| Status to understand | Ozone therapy is not FDA approved for the treatment of disease in the United States and is offered at physician discretion | Not FDA cleared for use in the United States. Established in European clinical practice, where published studies to date are limited in number and largely observational | The most established of the three, recognized in American Society for Apheresis guidelines for specific conditions |
EBOO is the shortest and lightest touch, focused on oxidative and circulatory support rather than removal. INUSpheresis is the selective one, built to take out specific large molecules while giving your own plasma back. TPE is the most established and the most aggressive, removing plasma wholesale and replacing it, which is why it is reserved for defined medical indications and requires replacement fluid.
None of these is a better therapy in the abstract. They answer different questions. Your candidacy assessment starts with what your testing shows, not with the technology.
Read more about EBOO therapy at AlyneMDIt helps to separate the technique from the specific system. Double filtration plasmapheresis, the method INUSpheresis uses, was introduced in the early 1980s and has been used since then in immune mediated, hematological, and neurological conditions. The mechanism is well characterized and the technique itself is long established.
The published work on the INUSpheresis system specifically is more recent and much smaller in scale. It consists largely of retrospective series and case reports rather than randomized controlled trials. Two recent European analyses examined how efficiently the system separates plasma and which circulating substances it captures, across a few dozen procedures in small patient groups.
This information is provided to support an informed discussion, not as an offer of INUSpheresis treatment. Dr. Sandhu can review your concerns and discuss available care or specialist evaluation. Read our physician review of INUSpheresis evidence and U.S. availability →
Selected references: Castillo-Aleman et al., Journal of Clinical Apheresis, 2025. Castillo-Aleman et al., Therapeutic Apheresis and Dialysis, 2026. Double filtration plasmapheresis was first described by Agishi et al. in the early 1980s.

INUSpheresis is a form of plasma filtration, not a general-purpose detox treatment. The procedure, its risks and the evidence for a particular indication should be evaluated separately.
Extracorporeal blood procedures are not risk-free. Medical screening, vascular access, anticoagulation and monitoring require specialist assessment. Risks vary by method and patient. INUSpheresis is not currently offered at AlyneMD.
A consultation begins with your symptoms, medical history and relevant testing. We discuss available care and specialist referral when appropriate. INUSpheresis is not currently an AlyneMD treatment option; ask Dr. Sandhu about longevity options during a consultation.
Session count varies based on your goals and medical profile.
Yes—many patients combine these therapies with peptide and metabolic protocols.
Plasma exchange is offered selectively and may be completed at a partner facility when advanced monitoring is needed.
EBOO exposes your blood to a medical oxygen and ozone mixture to support oxidative signaling and microcirculation, and takes about 45 to 60 minutes. INUSpheresis is a filtration therapy that separates your plasma and passes it through a size selective filter to remove larger molecules such as inflammatory cytokines and oxidized lipids, then returns your own plasma. It takes about 2 to 3 hours. EBOO adds. INUSpheresis removes.
No. Therapeutic plasma exchange removes your plasma entirely and replaces it with albumin or donor plasma. INUSpheresis filters your plasma and gives it back, so replacement fluid is usually not needed. That difference is why the two have different risk profiles and different indications.
Your medical history, symptoms and relevant testing guide the discussion. A consultation may lead to available treatment, further evaluation or specialist referral. It does not establish candidacy for every therapy discussed on this page; INUSpheresis is not currently offered at AlyneMD.
INUSpheresis is not currently offered at AlyneMD in Warren or New York. This page is educational. Call 908-888-9199 to discuss the services we offer; please do not book expecting an INUSpheresis procedure.